+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Obesity Drugs Market by Product Type (Glp-1 Agonists, Naltrexone Bupropion, Orlistat), Dosage Form (Capsules, Injectables, Tablets), Route Of Administration, End User - Global Forecast 2025-2030- Product Image
Anti-Obesity Drugs Market by Product Type (Glp-1 Agonists, Naltrexone Bupropion, Orlistat), Dosage Form (Capsules, Injectables, Tablets), Route Of Administration, End User - Global Forecast 2025-2030- Product Image
Sale

Anti-Obesity Drugs Market by Product Type (Glp-1 Agonists, Naltrexone Bupropion, Orlistat), Dosage Form (Capsules, Injectables, Tablets), Route Of Administration, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 191 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5317899
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Anti-Obesity Drugs Market is undergoing significant transformation driven by therapeutic innovation, regulatory evolution, and shifting stakeholder strategies. Senior decision-makers must navigate a landscape shaped by advanced pharmacological solutions, evolving value-based care models, and changing global trade dynamics to sustain growth and competitive advantage.

Market Snapshot: Anti-Obesity Drugs Market Trends and Growth

The Anti-Obesity Drugs Market grew from USD 4.09 billion in 2024 to USD 4.38 billion in 2025. It is expected to continue growing at a CAGR of 6.89%, reaching USD 6.11 billion by 2030. Market expansion is propelled by the rising prevalence of obesity, continued innovation in peptide-based pharmaceuticals, dynamic payer and regulatory responses, and stakeholder focus on patient-centric care models. The combination of strong R&D activity, emerging digital health integration, and adaptive manufacturing is redefining global and regional market opportunities for anti-obesity drugs.

Scope & Segmentation

This report delivers granular insight into the Anti-Obesity Drugs Market through defined segmentation, deep-dive regional analysis, and technology assessment to help leaders prioritize investments and develop informed strategic plans.

  • Product Types: Glucagon-like peptide 1 (GLP-1) agonists; naltrexone bupropion; orlistat; phentermine topiramate; SGLT2 inhibitors
  • Dosage Forms: Capsules; tablets; injectables (including prefilled pens and vials)
  • Routes of Administration: Oral; injectable (autoinjector, prefilled pen, vial); nasal
  • End Users: Clinics; homecare settings; hospitals
  • Regional Coverage: Americas (United States—including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina); Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland); Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Technology Landscape: Advancements in peptide-based drugs; fixed-dose combinations; digital health integration; innovative drug delivery systems
  • Company Coverage: Novo Nordisk A/S; Eli Lilly and Company; Pfizer Inc.; AstraZeneca PLC; Boehringer Ingelheim International GmbH; Amgen Inc.; Zealand Pharma A/S; Gelesis, Inc.; F. Hoffmann-La Roche AG; GlaxoSmithKline plc

Key Takeaways for Decision-Makers

  • Therapeutic advances in GLP-1 agonists and combination regimens are reshaping patient outcomes and clinical adoption patterns.
  • Growth in user-friendly injectable delivery platforms, such as prefilled pens and autoinjectors, is supporting broader patient adherence and expanding homecare use.
  • Adaptive regulatory pathways, amplified by real-world data integration, are expediting market access while upholding safety standards.
  • The evolution of digital health tools—from remote monitoring to telemedicine—strengthens engagement, improves adherence tracking, and helps gather crucial outcome data.
  • Strategic alliances, expanding regional manufacturing, and collaborations with academic and contract research organizations are deepening innovation pipelines and supporting supply resilience across markets.

Tariff Impact: Navigating Supply Chain and Trade Challenges

Shifts in United States tariff policies introduced in 2025 have altered supply chain economics for anti-obesity drug manufacturers. Companies are responding by near-shoring select production, partnering with domestic manufacturers, and revisiting procurement agreements to stabilize costs. These responses are driving further diversification of sourcing strategies and accelerating regional supply optimization as firms seek to buffer against continued trade policy volatility.

Methodology & Data Sources

This analysis integrates comprehensive secondary research—including peer-reviewed journals, regulatory filings, and proprietary databases—with targeted primary interviews of key stakeholders. The research team employs advanced statistical, segmentation, and scenario modeling techniques, bolstered by peer review, to ensure accuracy and actionable relevance.

Why This Report Matters

  • Equips senior leaders with actionable insights to navigate regulatory complexities and rapidly evolving therapeutic technologies.
  • Supports informed investment and operational decisions through detailed segmentation, regional analysis, and supplier mapping.
  • Enables organizations to anticipate tariff effects, capitalize on emerging digital health trends, and strengthen supply chain resilience.

Conclusion

The Anti-Obesity Drugs Market is evolving at pace, shaped by technological progress, shifting regulations, and strategic collaborations. Organizations investing in innovation, adaptive supply strategies, and digital integration are best positioned to lead, mitigate risk, and deliver sustainable patient value.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Physician prescribing preferences evolving toward GLP-1 receptor agonist combination therapies for weight management
5.2. Payers implementing step edit protocols to manage rising costs of novel anti-obesity medications
5.3. Direct to consumer marketing campaigns driving patient demand for injectable obesity treatments
5.4. Emergence of oral GLP-1 agonist formulations transforming patient adherence in obesity care
5.5. Phase III trials of dual GIP and GLP-1 agonists demonstrating superior weight loss and metabolic benefits
5.6. Health equity initiatives targeting racial and socioeconomic disparities in obesity drug access and outcomes
5.7. Telehealth platforms integrating obesity coaching with prescription medication adherence monitoring
5.8. Biotech startups leveraging precision medicine to develop peptide based therapies for targeted weight reduction
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-Obesity Drugs Market, by Product Type
8.1. Introduction
8.2. Glp-1 Agonists
8.3. Naltrexone Bupropion
8.4. Orlistat
8.5. Phentermine Topiramate
8.6. Sglt2 Inhibitors
9. Anti-Obesity Drugs Market, by Dosage Form
9.1. Introduction
9.2. Capsules
9.3. Injectables
9.3.1. Prefilled Pens
9.3.2. Vials
9.4. Tablets
10. Anti-Obesity Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Autoinjector
10.2.2. Prefilled Pen
10.2.3. Vial
10.3. Nasal
10.4. Oral
11. Anti-Obesity Drugs Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Homecare Settings
11.4. Hospitals
12. Americas Anti-Obesity Drugs Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Anti-Obesity Drugs Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Anti-Obesity Drugs Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Novo Nordisk A/S
15.3.2. Eli Lilly and Company
15.3.3. Pfizer Inc.
15.3.4. AstraZeneca PLC
15.3.5. Boehringer Ingelheim International GmbH
15.3.6. Amgen Inc.
15.3.7. Zealand Pharma A/S
15.3.8. Gelesis, Inc.
15.3.9. F. Hoffmann-La Roche AG
15.3.10. GlaxoSmithKline plc
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ANTI-OBESITY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. ANTI-OBESITY DRUGS MARKET: RESEARCHAI
FIGURE 24. ANTI-OBESITY DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 25. ANTI-OBESITY DRUGS MARKET: RESEARCHCONTACTS
FIGURE 26. ANTI-OBESITY DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTI-OBESITY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 87. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 88. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 89. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 90. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 91. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 92. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 93. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 94. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 95. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 96. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 97. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 100. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 101. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 102. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 103. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 104. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 105. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 106. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 107. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 108. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 109. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 162. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 163. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 164. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 165. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 166. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 167. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 168. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 169. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 170. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 171. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 174. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 175. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 176. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 177. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 178. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 179. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 182. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 183. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 195. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 198. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 199. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 200. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 201. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 202. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 203. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 204. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 205. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 206. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 207. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 210. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 211. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 212. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 213. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 214. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 215. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 216. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 217. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 218. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 219. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 258. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 259. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 260. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 261. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 262. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 263. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 264. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 265. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 266. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 267. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 273. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 274. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 275. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 278. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 279. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 282. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 283. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 284. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 285. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 286. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 287. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 290. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 291. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 294. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 295. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 296. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 297. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 298. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 299. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 300. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 301. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 302. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 303. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 305. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 306. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 307. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 308. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 309. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 310. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 311. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 312. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 313. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 314. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 315. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 316. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 317. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 318. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 319. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 320. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 321. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 322. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 323. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 324. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 325. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 326. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 327. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 328. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 329. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 330. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 331. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 332. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 333. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 334. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 335. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 336. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 337. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 338. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 339. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 340. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 341. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 342. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 343. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 344. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 345. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 346. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 347. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (

Samples

Loading
LOADING...

Companies Mentioned

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Pfizer Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Amgen Inc.
  • Zealand Pharma A/S
  • Gelesis, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc

Table Information

Report AttributeDetails
No. of Pages191
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.38 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.11 Billion
Compound Annual Growth Rate6.8%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Anti-Obesity Drugs Market Industry Trends and Global Forecasts to 2035, by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players - Product Image

Anti-Obesity Drugs Market Industry Trends and Global Forecasts to 2035, by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players

  • Report
  • 240 Pages
  • Global
From
North America Anti-Obesity Drugs Market Size, Share & Industry Trends Analysis Report By Drug Type, By Mechanism of Action, By Route Of Administration (Oral Route and Subcutaneous Route), By Distribution Channel, By Country and Growth Forecast, 2023-2029 - Product Image

North America Anti-Obesity Drugs Market Size, Share & Industry Trends Analysis Report By Drug Type, By Mechanism of Action, By Route Of Administration (Oral Route and Subcutaneous Route), By Distribution Channel, By Country and Growth Forecast, 2023-2029

  • Report
  • 72 Pages
  • North America
From
Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032 - Product Image

Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032

  • Report
  • 140 Pages
  • Asia Pacific
From
Anti-Obesity Drugs - Global Strategic Business Report - Product Image

Anti-Obesity Drugs - Global Strategic Business Report

  • Report
  • 264 Pages
  • Global
From
Anti-obesity Prescription Drugs Market by Drug Class (Amylin Analogs, GLP-1 Agonists, Lipase Inhibitors), Administration Route (Injectables, Orals), Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Anti-obesity Prescription Drugs Market by Drug Class (Amylin Analogs, GLP-1 Agonists, Lipase Inhibitors), Administration Route (Injectables, Orals), Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.